Document is current

Article History

Received: 7 February 2025

Accepted: 13 May 2025

First Online: 11 June 2025

Declarations

:

: Rajesh Pahwa is a member of the Editorial Board of Neurology and Therapy. Rajesh Pahwa was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Rajesh Pahwa, Eric Molho, Khashayar Dashtipour, Ramon A Gil, Fredy J Revilla, and Stuart H Isaacson were all investigators in the OPTIMYST study and report fees for consultancy from Supernus Pharmaceuticals, Inc. Rajesh Pahwa reports grants from Abbott, AbbVie, Alexza, Annovis, Biogen, Bluerock, Bukwang, Cerevel, Global Kinetics, Jazz, the Michael J Fox Foundation, NeuroDerm, Neuraly, the Parkinson’s Foundation, Praxis, Roche, Sage, Scion, Sun Pharma, UCB, and Voyager; and consulting fees from Abbott, AbbVie, ACADIA, Acorda, Allevion, Amneal, Artemida, BioVie, CalaHealth, Convatec, Global Kinetics, Inbeeo, Insightec, Jazz, Kyowa, Lundbeck, Merz, Neurocrine, NeuroDerm, Ono, PhotoPharmics, Sage, Sunovion, Supernus, UCB, and Wren. Eric Molho reports consultancy fees from CNS Ratings; speaker fees from Neurocrine Biosciences; research grants from Impax Pharmaceuticals, Civitas Therapeutics, Cure Huntington’s Disease Initiative, Michael J Fox Foundation, Biogen, Acorda Therapeutics, Biohaven Pharmaceuticals; and an educational grant from Merz Neurosciences. Mark Lew reports consultancy for Supernus Pharmaceuticals, Inc., Neurocrine, Acorda, Kyowa, Amneal, UCB, Merz, Acadia, and Abbvie; and research grants from the Michael J Fox Foundation, Neuraly, NIAA, Jazz Pharmaceuticals, UCB, Inhibikase Therapeutics, Biogen, and Ono Pharma. Khashayar Dashtipour has received compensation to serve as an advisor and/or speaker from Allergan, Acadia, Abbvie, Acorda, Amneal, Cynapsus, Ipsen, Kyowa Kirin, Lundbeck, Neurocrine, Revance, Supernus, Teva, and US WorldMeds. Ramon A Gil reports fees for speaking engagements consultancy from US WorldMeds, LLC. Fredy J Revilla reports consultancy fees from US WorldMeds, LLC. Stuart Isaacson reports receipt of grants and/or research support from Abbvie, Amneal, Bial, Biogen, Ipsen, Lundbeck, Michael J Fox Foundation, Neurocrine, Neuroderm, Parkinson Study Group, Revance, Roche, Supernus, Teva, Theravance, and UCB; receipt of consulting fees from Abbvie, Acadia, Amneal, Cerevance, Kirin, Merz, Neurocrine, Neuroderm, Revance, Roche, Supernus, Teva, and UCB; and participation in a company sponsored speaker’s bureau for Abbvie, Acadia, Amneal, Kyowa Kirin, Merz, Neurocrine, Supernus, and Teva. Thomas Clinch was an employee of US WorldMeds, LLC (currently MDD, US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc.) at the time the study was conducted. His current affiliation is USWM, LLC (Louisville, KY, USA). Peibing Qin is an employee of Supernus Pharmaceuticals, Inc.

: Institutional review boards at the participating sites approved the protocol, and the trial was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines. All patients provided written informed consent.